BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
5 Wellbeing Applications Assist You With remaining Fit- Step by step instructions to Utilize Open Record Rewards for Your Potential benefit
- Vote in favor of Your Number one Cake Type
- Monetary Security: Building Areas of strength for an Establishment
- AI is making spacecraft propulsion more efficient – and could even lead to nuclear-powered rockets
- Manual for Notorious Fragrances: Immortal Aromas
- Experiences in Natural life Protection: Individual Progressives' Excursions
- Which camera do you believe is great for first-time clients? !
- The Ascent of Rousing Pioneers Who Formed History
